* known hypersensitivity to any component of the imp. * history of allergic disease or reactions likely to be exacerbated by any component of the imp. * previous hypersensitivity, infusion related reaction or severe adverse reaction following administration of mabs. * fever above 38.0°c on day prior to or on day of randomisation/dosing. * ast, alt or serum creatinine above uln; bilirubin and alp \>1.5 × uln. * any vaccination except for covid-19 vaccine (e.g., inactivated influenzae vaccine) planned. * sars cov-2 or covid-19: receipt of a covid-19 vaccine within 3 months. covid-19 infection within 3 months prior.

* known hypersensitivity to any component of the imp. * history of allergic disease or reactions likely to be exacerbated by any component of the imp. * previous hypersensitivity, infusion related reaction or severe adverse reaction following administration of mabs. * fever above 38.0°c on day prior to or on day of randomisation/dosing. * ast, alt or serum creatinine above uln; bilirubin and alp \>1.5 × uln. * any vaccination except for covid-19 vaccine (e.g., inactivated influenzae vaccine) planned. * sars cov-2 or covid-19: receipt of a covid-19 vaccine within 3 months. covid-19 infection within 3 months prior.

known hypersensitivity to any component of the imp. history of allergic disease or reactions likely to be exacerbated by any component of the imp. previous hypersensitivity, infusion related reaction or severe adverse reaction following administration of mabs. fever above 38.0°c on day prior to or on day of randomisation/dosing. ast, alt or serum creatinine above uln; bilirubin and alp >1.5 × uln. any vaccination except for covid-19 vaccine (e.g., inactivated influenzae vaccine) planned. sars cov-2 or covid-19: receipt of a covid-19 vaccine within 3 months. covid-19 infection within 3 months prior.

known hypersensitivity to any component of the imp. history of allergic disease or reactions likely to be exacerbated by any component of the imp. previous hypersensitivity, infusion related reaction or severe adverse reaction following administration of mabs. fever above 38.0°c on day prior to or on day of randomisation/dosing. ast, alt or serum creatinine above uln; bilirubin and alp >1.5 × uln. any vaccination except for covid-19 vaccine (e.g., inactivated influenzae vaccine) planned. sars cov-2 or covid-19: receipt of a covid-19 vaccine within 3 months. covid-19 infection within 3 months prior.